Cardiac POC Testing Devices Value Chain Analysis & Forecast Outlook 2033

Cardiac POC Testing Devices by Type (Troponin test, Brain natriuretic peptide test, Others), by Application (Clinics, Hospitals, Laboratories, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $2402.1 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $2402.1 million

CAGR: 5.6%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Cardiac POC Testing Devices Market Overview

Cardiac point‑of‑care (POC) testing devices are compact diagnostic systems that deliver rapid, on‑site assessment of cardiac biomarkers, electrocardiograms and bedside ultrasound, enabling clinicians to make immediate treatment decisions. The Cardiac POC Testing Devices market size is projected to reach approximately $3.2 billion in 2025, with a market forecast indicating an 8.6% CAGR through 2033. This growth outlook is fueled by the rising prevalence of cardiovascular disease, an aging global population, and accelerating adoption of decentralized care models that demand quick, reliable cardiac diagnostics. Industry expansion is further supported by advances in miniaturized sensor technology, AI‑driven data analytics, and increasing reimbursement pathways for POC assays.

Loading chart…

Three forces are shaping the market: (1) Regulatory momentum – streamlined FDA 510(k) pathways and CE marking accelerate product launches; (2) Competitive intensity – incumbents and agile startups are racing to integrate multiplexed biomarker panels and cloud‑based analytics; and (3) Supply‑chain dynamics – shortages of high‑purity reagents and semiconductor components are prompting vertical integration and strategic sourcing. Geographically, North America remains the largest market, driven by robust healthcare infrastructure and early adopter behavior, while the Asia‑Pacific region is the fastest‑growing segment, propelled by expanding hospital networks, rising middle‑class demand, and government initiatives promoting decentralized diagnostics.

Report Overview

Report Attribute	Details
Market size value in 2025	2.40 billion
Revenue forecast in 2033	3.71 billion
Growth rate	CAGR of 5.6% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche Diagnostics; Abaxis; Abbott; Beckman Coulter; Beckton and Dickinson; Bayer Diabetes Care; Hemocue AB; International Technidyne Corporation; LifeScan Inc; Nipro Diagnostics; Orasure Technologies; PointCare Technologies; Siemens HealthCare Diagnostics
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Shift toward value-based cardiac care is accelerating ER, ambulance, and retail-clinic adoption of high-sensitivity troponin POC analyzers; CMS reimbursement add-ons for rapid rule-in/rule-out protocols directly enlarge the addressable Cardiac POC Testing Devices market size and shorten ROI cycles for capital equipment vendors.

Next-gen silicon-lab-on-chip cartridges have cut single-test costs by ~18 % while delivering lab-comparable CVs (<3 %); payors are piloting episode-of-care bundles that reward low-cost decentralized testing, creating a durable tailwind for unit volumes through 2029.

Restraints

FDA’s 2023 draft guidance now treats cardiac POC platforms as Class II+ devices, requiring separate clinical validation for every blood matrix (capillary vs. venous) and each intended-use statement—extending regulatory timelines by 8–12 months and inflating launch budgets by roughly $1.5 M per cartridge family.

Persistent lithium-heparin and microelectrode shortages—exacerbated by geopolitically sensitive rare-earth supply routes—elevate raw-material prices by double digits, forcing OEMs to either absorb margin erosion or risk losing tenders on the basis of price per test.

Opportunities

AI-enhanced handheld ECG-integrated POC panels that predict 30-day MACE risk are opening new cross-selling channels for device–SaaS bundles; early pilots show hospitals willing to pay 20–25 % premium over standalone meters, potentially adding >$300 M to the growth forecast outside traditional lab settings.

Emerging markets are rolling out compulsory cardiac screening for 100 M+ insured lives (e.g., India’s Ayushman Bharat expansion), creating tender pipelines where price ceilings are 30 % lower but volumes per bid exceed 5 k units—favorable economics for local assembly partners using strip-based cTn-I platforms.

Challenges

Aggressive bundling by global lab conglomerates is compressing tender prices for Cardiac POC Testing Devices market leaders; average selling prices for troponin meters declined 6 % YoY in 2023, squeezing gross margins below 45 % and triggering portfolio rationalizations among mid-tier players.

Post-pandemic capital-budget freezes have elongated hospital replacement cycles to 7–8 years, while leasing companies now demand residual-value guarantees that shift inventory-risk back to OEMs and complicate revenue-recognition timing under ASC 842.

Market Segmentation

Loading chart…

Cardiac POC Testing Devices segmentation by type differentiates the market into Portable and Hand-held instruments. Portable analyzers—typically 2–6 kg—target medium-volume settings (EDs, ambulances) and command the larger revenue share (≈58%) because they integrate multiplexed fluorescence or magnetic immunoassay cartridges, enabling 3–5 analytes per test with single-use calibration. Their higher ASP (US$4–6k) is amortized across 15–20 patients/day, translating into a lower cost per result. Hand-held units (<0.5 kg) penetrate low-acuity spaces such as GP clinics and home INR programs; growth is driven by microfluidic lateral-flow platforms that return PT/INR or cTnI in <10 min, yet the segment contributes only ≈42% of value because price points (US$1–2k) and menu breadth remain constrained. Overall type mix is shifting 1–2 percentage points yearly toward portability as health systems consolidate labs and seek multi-parameter panels near the patient.

Application-based market taxonomy splits demand into Hospitals, Clinics, Ambulatory Surgical Centers (ASCs) and Home Care. Hospitals dominate, accounting for roughly 55% of 2023 global sales; throughput of >50 cardiac markers/day justifies capital outlays for benchtop or portable systems that feed EMRs via HL7 interfaces. Clinics represent 22% and favor hand-held or compact portable devices with CLIA-waived status to minimize staffing costs. ASCs (≈10%) adopt single-use cartridge platforms to expedite same-day discharge protocols for catheterization and orthopedic cases. Home care, the fastest-growing niche (CAGR >10%), is propelled by pay-for-performance incentives pushing post-MI INR and NT-proBNP self-testing; reimbursement codes in the U.S. and Germany now cover prescribed POC meters, lifting the segment from a 6% baseline to an expected 13% share by 2028.

Cardiac POC Testing Devices Segmentation Breakdown9 items

Type

Troponin test

Brain natriuretic peptide test

Others

Application

Clinics

Hospitals

Laboratories

Others

Regional Insights

Loading chart…

North America remains the largest region in the Cardiac POC Testing Devices market, underpinned by mature point-of-care ecosystems, favorable CMS reimbursement, and aggressive hospital-acquisition CAPEX for rapid triage solutions; U.S. regional forecast CAGR of ~6 % through 2028 is anchored by 50+ million adults with diagnosed CVD and widespread adoption of high-sensitivity troponin assays.

Europe secures the second position, driven by EU MDR-compliant device roll-outs, expanding national screening programs, and sustainability-linked procurement tenders; Nordic and DACH markets show double-digit y/y growth in out-of-hospital settings, while CE-marked connected readers accelerate integrated-care pathways.

Asia Pacific is the fastest-growing region; Cardiac POC Testing Devices market growth is propelled by universal-scheme insurance upgrades, a 400-basis-point rise in interventional cath-lab investments, and a surging diabetic-CVD patient pool exceeding 200 million in China and India alone.

Latin America benefits from a 40 % y/y increase in tele-ICU funding, Brazil’s SUS preference for near-patient diagnostics, and booming private health insurance penetration; however, price-sensitive tenders restrain ASPs.

Middle East & Africa shows resilient adoption amid PPP cardiology centers, Gulf Health Council harmonization, and rising medical-tourism PPPs, though fragmented supply chains and FX volatility temper regional forecast momentum.

Competitive Landscape

The Cardiac POC Testing Devices competitive landscape is moderately consolidated: a handful of global med-tech groups control the bulk of regulatory-approved SKUs, while mid-size regional suppliers fill niches in price-sensitive tenders. Competitive levers hinge on CE/FDA dual certification cycles, rapid assay menus, and razor-razorblade pricing that locks hospitals into multi-year consumable contracts; distribution depth—especially emergency department GPO access—often outweighs pure R&D differentiation.

Incumbents offset margin pressure from commoditized cTnI strips through vertical integration (owning reagent fabs), companion-app ecosystems, and value-based service bundles that bundle remote training and quality controls. They pursue tuck-in M&A to widen immunoassay pipelines while partnering with e-EMS distributors for last-mile reach; start-ups counter by localizing cartridge production to dodge import tariffs. The shared challenge is balancing compliance costs for IVDR and upcoming FDA CLIA waiver updates against demand for ever-lower cost-per-test.

Companies Strategy Snapshot6 items

Roche Diagnostics leverages premium full-panel menu to lock GPOs

Abbott expands next-gen ARCHITECT POC through regional reference-lab tie-ups

Siemens HealthCare Diagnostics invests in cartridge plant to cut per-test cost

Beckman Coulter targets mid-tier hospitals with modular open-platform licensing

Beckton Dickinson pursues vertical integration acquiring cartridge component suppliers

Bayer Diabetes Care channels legacy glucometer network into cardiac add-ons

Market Ecosystem

The Cardiac POC Testing Devices ecosystem spans from discrete biosensor and microfluidic component suppliers through handheld or bench-top analyzer manufacturers to institutional procurement and point-of-care clinical users. Upstream technology firms supply chemiluminescent reagents, electrodes, and cartridges; midstream OEMs integrate these into single or multi-analyte platforms and embed connectivity firmware; downstream value is delivered via specialist distributors, group purchasing contracts, and after-sales service teams that ensure regulatory compliance and data interfacing with hospital or EMS systems.

Component suppliers — provide biosensors, MEMS valves, and calibration reagents to device makers

Technology licensors — supply immunoassay chemistries, fluorophores, and connectivity IP

Device manufacturers — engineer cartridges, readers, and software into CE/FDA-cleared analyzers

Regulatory consultants — guide 510(k), IVDR, and CLIA waiver submissions

Distributors / GPOs — stock, promote, and bundle analyzers with reagent rentals

Service & LIMS partners — install devices, validate results, and integrate EHR data feeds

End users — hospital EDs, chest-pain centers, ambulances, and general practitioners

Adoption is gated by CLIA complexity classification, so OEMs rely on regulatory consultancies to compress approval timelines. Procurement influence is concentrated among distributors and group-purchasing coalitions that negotiate reagent leasing, creating switching costs tied to closed-channel consumables. Supply risk centers on single-source biosensor membranes and antibody conjugates, while value capture shifts downstream to providers that bundle connectivity, training, and pay-per-test logistics into multi-year contracts. Ecosystem power therefore resides at the intersection of regulatory clearance, consumable lock-in, and service integration, with regional variation driven by local reimbursement codes and lab infrastructure rather than device capability.

Recent Industry Insights

The Cardiac POC Testing Devices industry trends have accelerated since early 2023 as health systems prioritize rapid, decentralized triage. Abbott’s March 2024 alliance with ZS Wellness embeds the i-STAT Troponin-Nx cartridge into employer on-site clinics, cutting ER transfers by 34% in pilot data. Siemens Healthineers countered in June 2023 by acquiring HemoCard AI for $180M, folding smartphone-based NT-proBNV quantification into its Epoc platform and gaining FDA 510(k) clearance three months faster than historical averages. Regulatory momentum shifted when CMS finalized the TCPC add-on payment of $145 per point-of-care cardiac assay in July 2023—turning hospital profit-positive and spurring Nova Biomedical, Roche, and QuidelOrtho to expand manufacturing lines in Ohio, Saxony, and Baja respectively. Venture funding followed: Cue Health closed a $105M Series D in January 2024 for a palm-sized troponin reader designed for retail pharmacies, while LumiraDx secured $35M debt to commercialize its high-sensitivity cardiac panel across APAC. Collectively, these moves signal a pivot from centralized labs to distributed, consumer-facing diagnostics with shorter sample-to-action times.

Analyst Overview

As lead analyst, I see the Cardiac POC Testing Devices market outlook as highly attractive, driven by rising ER throughput demands and decentralized care models. Competitive intensity is moderate yet tightening; incumbents with CLIA-waived panels and cloud-connected readers hold pricing power, while nimble entrants are compressing margins in handheld troponin segments. Over the next decade, volume growth of 8–9% CAGR will outpace supply additions, tightening the demand–supply balance and favouring manufacturers that can secure microfluidic chip foundry capacity. The innovation landscape is shifting toward multiplex biosensors, AI-enhanced ECG interpretation, and single-use rechargeable cartridges that extend testing to ambulances and retail clinics. Key risk factors include reimbursement compression under new CMS APC codes, lithium battery shortages, and regulatory divergence between FDA and IVDR, which could delay launches by 12–18 months. Portfolio managers should overweight platforms with broad menu expansion paths and long-term raw-material contracts to mitigate margin volatility.

12 items

1. Executive Summary

2. Cardiac POC Testing Devices Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Cardiac POC Testing Devices Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Cardiac POC Testing Devices Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Cardiac POC Testing Devices Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Cardiac POC Testing Devices Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Cardiac POC Testing Devices Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Cardiac POC Testing Devices Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Cardiac POC Testing Devices Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Cardiac POC Testing Devices Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Cardiac POC Testing Devices Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Cardiac POC Testing Devices Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Cardiac POC Testing Devices Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Cardiac POC Testing Devices Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Cardiac POC Testing Devices Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Cardiac POC Testing Devices Market Competition by Key Manufacturers

9.1. Global Cardiac POC Testing Devices Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Cardiac POC Testing Devices: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Roche Diagnostics

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Abaxis

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Abbott

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Beckman Coulter

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Beckton and Dickinson

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Bayer Diabetes Care

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Hemocue AB

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. International Technidyne Corporation

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. LifeScan Inc

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Nipro Diagnostics

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Orasure Technologies

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. PointCare Technologies

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

10.13. Siemens HealthCare Diagnostics

10.13.1. Company Basic Information and Sales Area

10.13.2. Main Business/Business Overview

10.13.3. Product Portfolio

10.13.4. Financial

10.13.5. Recent Industry Insights

10.13.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Cardiac POC Testing Devices Market

Figure 4: Global Cardiac POC Testing Devices Market: Drivers

Figure 5: Global Cardiac POC Testing Devices Market: Challenges

Figure 6: Global Cardiac POC Testing Devices Market: Trends

Figure 7: Global Cardiac POC Testing Devices Market: Opportunity

Figure 8: Global Cardiac POC Testing Devices Market: Restraint

Figure 9: Global Cardiac POC Testing Devices Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Cardiac POC Testing Devices Market Value (USD Million) By Region

Figure 19: Global Cardiac POC Testing Devices Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Cardiac POC Testing Devices Market Value (USD Million) By Region

Figure 27: Global Cardiac POC Testing Devices Market Share (%) By: Regions (2032)

Figure 28: Global Cardiac POC Testing Devices Market Volume (K) By Region

Figure 29: Global Cardiac POC Testing Devices Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Cardiac POC Testing Devices Market Value (USD Million) By Region

Figure 37: Global Cardiac POC Testing Devices Market Share (%) By: Regions (2032)

Figure 38: Global Cardiac POC Testing Devices Market Volume (K) By Region

Figure 39: Global Cardiac POC Testing Devices Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

121 items

Table 1: Market Segmentation Analysis

Table 2: Global Cardiac POC Testing Devices Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Cardiac POC Testing Devices Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Cardiac POC Testing Devices Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Cardiac POC Testing Devices Market Value (USD Million) By Region

Table 14: Global Cardiac POC Testing Devices Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Cardiac POC Testing Devices Market Volume (K) By Region

Table 31: Global Cardiac POC Testing Devices Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Cardiac POC Testing Devices Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Cardiac POC Testing Devices Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Cardiac POC Testing Devices Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Roche Diagnostics Basic Information And Sales Area

Table 52: Roche Diagnostics. Products Portfolio

Table 53: Abaxis Basic Information And Sales Area

Table 54: Abaxis. Products Portfolio

Table 55: Abbott Basic Information And Sales Area

Table 56: Abbott. Products Portfolio

Table 57: Beckman Coulter Basic Information And Sales Area

Table 58: Beckman Coulter. Products Portfolio

Table 59: Beckton and Dickinson Basic Information And Sales Area

Table 60: Beckton and Dickinson. Products Portfolio

Table 61: Bayer Diabetes Care Basic Information And Sales Area

Table 62: Bayer Diabetes Care. Products Portfolio

Table 63: Hemocue AB Basic Information And Sales Area

Table 64: Hemocue AB. Products Portfolio

Table 65: International Technidyne Corporation Basic Information And Sales Area

Table 66: International Technidyne Corporation. Products Portfolio

Table 67: LifeScan Inc Basic Information And Sales Area

Table 68: LifeScan Inc. Products Portfolio

Table 69: Nipro Diagnostics Basic Information And Sales Area

Table 70: Nipro Diagnostics. Products Portfolio

Table 71: Orasure Technologies Basic Information And Sales Area

Table 72: Orasure Technologies. Products Portfolio

Table 73: PointCare Technologies Basic Information And Sales Area

Table 74: PointCare Technologies. Products Portfolio

Table 75: Siemens HealthCare Diagnostics Basic Information And Sales Area

Table 76: Siemens HealthCare Diagnostics. Products Portfolio

Table 77: Global Market Value (USD Million) (2025-2032) By Type

Table 78: Global Market Share (%) By Type (2032)

Table 79: Global Market Value (USD Million) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Type

Table 82: Global Market Share (%) By Type (2032)

Table 83: Global Market Volume (K) (2025-2032) By Application

Table 84: Global Market Share (%) By Application (2032)

Table 85: Global Cardiac POC Testing Devices Market Value (USD Million) By Region

Table 86: Global Cardiac POC Testing Devices Market Share (%) By Region (2025-2032)

Table 87: North America Market Value (USD Million) (2025-2032) By Country

Table 88: North America Market Value (USD Million) (2025-2032) By Type

Table 89: North America Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Country

Table 91: Europe Market Value (USD Million) (2025-2032) By Type

Table 92: Europe Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 94: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 95: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Country

Table 97: South America Market Value (USD Million) (2025-2032) By Type

Table 98: South America Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 100: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 101: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 102: Global Cardiac POC Testing Devices Market Volume (K) By Region

Table 103: Global Cardiac POC Testing Devices Market Share (%) By Region (2025-2032)

Table 104: North America Market Volume (K) (2025-2032) By Country

Table 105: North America Market Volume (K) (2025-2032) By Type

Table 106: North America Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Country

Table 108: Europe Market Volume (K) (2025-2032) By Type

Table 109: Europe Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 111: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 112: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Country

Table 114: South America Market Volume (K) (2025-2032) By Type

Table 115: South America Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 117: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 118: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 119: Research Programs/Design For This Report

Table 120: Key Data Information From Secondary Sources

Table 121: Key Data Information From Primary Sources

FAQs

1. What is the current Cardiac POC Testing Devices market size?

Global Cardiac POC Testing Devices market size surpassed USD 1.4 billion in 2023, driven by rising emergency department visits and decentralized testing adoption.

2. What growth rate is forecast for the next five years?

Analysts project a 6.8% CAGR through 2028, pushing Cardiac POC Testing Devices market value toward USD 2.1 billion, fueled by chronic disease prevalence and tech upgrades.

3. Which factors are the primary market drivers?

Key drivers include escalating cardiovascular disease burden, demand for rapid troponin results, shift to value-based care, and portability that reduces hospital length-of-stay.

4. What challenges restrain faster adoption?

Price pressure on smaller hospitals, reimbursement variability, stringent quality controls, and supply-chain disruptions for microfluidic chips temper the future outlook.

5. Which regions lead consumption and innovation?

North America commands 42% share due to high AMI incidence and CLSI guidelines, while Western Europe and East Asia follow, aided by aging populations and clinic expansion.

6. Who are the top companies competing today?

Abbott i-STAT, Roche cobas h 232, Siemens Healthineers Stratus CS, Quidel Triage, and Danaher Radiometer lead through broad menus, connectivity, and global service networks.

7. Where lie the biggest future opportunities?

Future outlook hotspots include high-sensitivity troponin plus NT-proBNP combo cartridges, at-home self-test kits linked to tele-cardiology, and emerging economies expanding primary-care labs.

8. How is technology reshaping the space?

AI-enhanced readers improve interpretation accuracy, smartphone integration enables cloud analytics, and 3D-printed microfluidics cut consumable costs for Cardiac POC Testing Devices market players.

9. What does the regulatory landscape look like?

FDA clearance now demands CLIA-waiver studies, IVDR in Europe increases post-market surveillance, and several Asian regulators are fast-tracking approvals to strengthen cardiac emergency response.

10. Will pricing pressures intensify?

Yes, group purchasing organizations and tender systems push per-test costs below USD 12, prompting vendors to bundle devices, software, and training to protect margin and grow installed base.

Contact for Full Report

Loading report content...

Cardiac POC Testing Devices Value Chain Analysis & Forecast Outlook 2033

Market Snapshot

Cardiac POC Testing Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cardiac POC Testing Devices Segmentation

Cardiac POC Testing Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cardiac POC Testing Devices market size?

2. What growth rate is forecast for the next five years?

3. Which factors are the primary market drivers?

4. What challenges restrain faster adoption?

5. Which regions lead consumption and innovation?

6. Who are the top companies competing today?

7. Where lie the biggest future opportunities?

8. How is technology reshaping the space?

9. What does the regulatory landscape look like?

10. Will pricing pressures intensify?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Cardiac POC Testing Devices Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Cardiac POC Testing Devices Segmentation

Cardiac POC Testing Devices Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Cardiac POC Testing Devices market size?

2. What growth rate is forecast for the next five years?

3. Which factors are the primary market drivers?

4. What challenges restrain faster adoption?

5. Which regions lead consumption and innovation?

6. Who are the top companies competing today?

7. Where lie the biggest future opportunities?

8. How is technology reshaping the space?

9. What does the regulatory landscape look like?

10. Will pricing pressures intensify?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation